Treating difficult crystal pyrophosphate dihydrate deposition disease

Area of Science:

• Rheumatology
• Metabolic Bone Disease
• Crystal Arthropathies

Background:

• Calcium pyrophosphate dihydrate (CPPD) deposition disease is a prevalent metabolic arthropathy.
• Early-onset CPPD (patients ≤ 60 years) necessitates investigation for underlying metabolic disorders, notably hemochromatosis.
• Current treatments do not halt joint destruction, emphasizing symptomatic relief.

Purpose of the Study:

• To review the diagnostic considerations and therapeutic strategies for calcium pyrophosphate dihydrate deposition disease.
• To highlight the importance of identifying associated metabolic conditions in early disease presentation.
• To outline effective symptomatic treatments and alternative options for refractory cases.

Main Methods:

• Literature review of calcium pyrophosphate dihydrate deposition disease.
• Analysis of treatment modalities including NSAIDs, corticosteroids, colchicine, magnesium, and methotrexate.
• Discussion of diagnostic workup for associated metabolic conditions.

Main Results:

• Nonsteroidal anti-inflammatory drugs and glucocorticoids are primary symptomatic treatments.
• Colchicine is effective for recurrent pseudogout attacks.
• Magnesium may offer preventive benefits, and methotrexate shows promise in refractory cases.

Conclusions:

• Early diagnosis of CPPD disease requires screening for metabolic conditions like hemochromatosis.
• Symptomatic treatment is the cornerstone of management, with various agents available.
• Methotrexate represents a potential option for patients unresponsive to standard therapies.